Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Pharmaceuticals and InvaGen Pharmaceuticals have entered into a collaboration agreement for the joint development and marketing of seven generic pharmaceutical products for the US market.
Subscribe to our email newsletter
The product list includes a mixture of off-patent and patent-protected molecules with cumulative annual sales in the US of approximately $4.1 million, according to Glenmark.
Pursuant to the agreement, InvaGen will develop and license to Glenmark, seven generic products. Glenmark will be responsible for obtaining regulatory approval in the US market and will exclusively market the products while InvaGen will be responsible for their manufacture and supply.
All development and regulatory costs and profits on sale in the US will be shared equally between Glenmark and InvaGen. Of the list, one abbreviated new drug application (ANDA) has already been made and three more are expected to be filed by March 2006.
Glenmark had also signed a collaboration agreement with another Indian company, Shasun Chemicals and Drugs for the joint development and marketing of 13 generic products in the US market. Shasun is expected to file two of its ANDAs under this agreement by March 2006.
Glenn Saldanha, managing director and CEO of Glenmark said: “We are happy to take our association with InvaGen even further. The deal is also in line with our multi-pronged approach to strengthen our presence as a serious generics player in the US market.”